164 related articles for article (PubMed ID: 35462597)
1. QbD-based optimization of raloxifene-loaded cubosomal formulation for transdemal delivery: ex vivo permeability and in vivo pharmacokinetic studies.
Gupta T; Kenjale P; Pokharkar V
Drug Deliv Transl Res; 2022 Dec; 12(12):2979-2992. PubMed ID: 35462597
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
Jain A; Sharma T; Kumar R; Katare OP; Singh B
Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178
[TBL] [Abstract][Full Text] [Related]
3. Self-Assembling Raloxifene Loaded Mixed Micelles: Formulation Optimization, In Vitro Cytotoxicity and In Vivo Pharmacokinetics.
Kanade R; Boche M; Pokharkar V
AAPS PharmSciTech; 2018 Apr; 19(3):1105-1115. PubMed ID: 29181706
[TBL] [Abstract][Full Text] [Related]
4. QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies.
Pant A; Sharma G; Saini S; Kaur G; Jain A; Thakur A; Singh B
Drug Deliv Transl Res; 2024 Mar; 14(3):730-756. PubMed ID: 37768530
[TBL] [Abstract][Full Text] [Related]
5. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
Saini D; Fazil M; Ali MM; Baboota S; Ali J
Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
[TBL] [Abstract][Full Text] [Related]
6. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal.
Elsheikh MA; Elnaggar YS; Gohar EY; Abdallah OY
Int J Nanomedicine; 2012; 7():3787-802. PubMed ID: 22888234
[TBL] [Abstract][Full Text] [Related]
7. Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability.
Du X; Gao N; Song X
Drug Deliv; 2021 Dec; 28(1):252-260. PubMed ID: 33501870
[TBL] [Abstract][Full Text] [Related]
8. In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance.
Ahmed OA; Badr-Eldin SM
Int J Nanomedicine; 2018; 13():6325-6335. PubMed ID: 30349253
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene encapsulated spanlastic nanogel for the prevention of bone fracture risk via transdermal administration: Pharmacokinetic and efficacy study in animal model.
Ansari MD; Shafi S; Pandit J; Waheed A; Jahan RN; Khan I; Vohora D; Jain S; Aqil M; Sultana Y
Drug Deliv Transl Res; 2024 Jun; 14(6):1635-1647. PubMed ID: 37996726
[TBL] [Abstract][Full Text] [Related]
10. Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application.
Mahmood S; Taher M; Mandal UK
Int J Nanomedicine; 2014; 9():4331-46. PubMed ID: 25246789
[TBL] [Abstract][Full Text] [Related]
11. Nanostructured Lipid Carrier-Based Codelivery of Raloxifene and Naringin: Formulation, Optimization, In Vitro, Ex Vivo, In Vivo Assessment, and Acute Toxicity Studies.
Alhalmi A; Amin S; Khan Z; Beg S; Al Kamaly O; Saleh A; Kohli K
Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145519
[TBL] [Abstract][Full Text] [Related]
12. Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers.
Murthy A; Ravi PR; Kathuria H; Malekar S
Nanomaterials (Basel); 2020 May; 10(6):. PubMed ID: 32486508
[TBL] [Abstract][Full Text] [Related]
13. Formulation and evaluation of cubosomes containing colchicine for transdermal delivery.
Nasr M; Younes H; Abdel-Rashid RS
Drug Deliv Transl Res; 2020 Oct; 10(5):1302-1313. PubMed ID: 32399604
[TBL] [Abstract][Full Text] [Related]
14. Poly (ε-caprolactone) nanocapsules for oral delivery of raloxifene: process optimization by hybrid design approach, in vitro and in vivo evaluation.
Aditya N; Ravi PR; Avula US; Vats R
J Microencapsul; 2014; 31(5):508-18. PubMed ID: 24697167
[TBL] [Abstract][Full Text] [Related]
15. Nanosized Cubosomal Thermogelling Dispersion Loaded with Saquinavir Mesylate to Improve Its Bioavailability: Preparation, Optimization, in vitro and in vivo Evaluation.
Hosny KM
Int J Nanomedicine; 2020; 15():5113-5129. PubMed ID: 32764940
[TBL] [Abstract][Full Text] [Related]
16. Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies.
Selvaraj BR; Sridhar SK; Kesavan BR; Palagati S
Pharm Nanotechnol; 2020; 8(6):452-470. PubMed ID: 32988361
[TBL] [Abstract][Full Text] [Related]
17. Physically Optimized Nano-Lipid Carriers Augment Raloxifene and Vitamin D Oral Bioavailability in Healthy Humans for Management of Osteoporosis.
Hosny KM; Bahmdan RH; Alhakamy NA; Alfaleh MA; Ahmed OA; Elkomy MH
J Pharm Sci; 2020 Jul; 109(7):2145-2155. PubMed ID: 32194094
[TBL] [Abstract][Full Text] [Related]
18. Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal.
Singh G; Pai RS
Drug Deliv; 2016; 23(2):532-9. PubMed ID: 24963752
[TBL] [Abstract][Full Text] [Related]
19. Optimized semisolid self-nanoemulsifying system based on glyceryl behenate: A potential nanoplatform for enhancing antitumor activity of raloxifene hydrochloride in MCF-7 human breast cancer cells.
Badr-Eldin SM; Aldawsari HM; Ahmed OAA; Alhakamy NA; Neamatallah T; Okbazghi SZ; Fahmy UA
Int J Pharm; 2021 May; 600():120493. PubMed ID: 33744452
[TBL] [Abstract][Full Text] [Related]
20. Verapamil-Loaded Cubosomes for Enhancing Intranasal Drug Delivery: Development, Characterization, Ex Vivo Permeation, and Brain Biodistribution Studies.
Faisal MM; Gomaa E; Ibrahim AE; El Deeb S; Al-Harrasi A; Ibrahim TM
AAPS PharmSciTech; 2024 May; 25(5):95. PubMed ID: 38710921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]